TransThera Sciences (Nanjing) (FRA:J8J) Institutional Ownership: 0.09% (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8J TransThera Sciences (Nanjing) Inc FRA:J8J
20 GF Score
Price €1.05
! 2 Warning Signs
View Full Analysis

What is TransThera Sciences (Nanjing) Institutional Ownership?

TransThera Sciences (Nanjing) FRA:J8J -0.94% 20 Institutional Ownership is 0.09% as of Aug. 22, 2026. GuruFocus rates FRA:J8J with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TransThera Sciences (Nanjing)'s institutional ownership is 0.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TransThera Sciences (Nanjing)'s Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TransThera Sciences (Nanjing)'s Float Percentage Of Total Shares Outstanding is 0.00%.

TransThera Sciences (Nanjing) Institutional Ownership Historical Data

* Premium members only.

The historical data trend for TransThera Sciences (Nanjing)'s Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransThera Sciences (Nanjing) Institutional Ownership Chart

TransThera Sciences (Nanjing) Historical Data

The historical data trend for TransThera Sciences (Nanjing) can be seen below:

2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 0.11 0.13 0.12 0.12 0.13 0.11 0.12 0.09
FRA:J8J
20GF Score
TransThera Sciences (Nanjing) Inc FRA:J8J
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransThera Sciences (Nanjing) Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.09% mean?
TransThera Sciences (Nanjing) (FRA:J8J) has a Institutional Ownership of 0.09% as of Aug. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TransThera Sciences (Nanjing) and its competitors.
Is TransThera Sciences (Nanjing)'s Institutional Ownership too high?
TransThera Sciences (Nanjing)'s current Institutional Ownership is 0.09%. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s Institutional Ownership compare to VRTX and REGN?
TransThera Sciences (Nanjing)'s Institutional Ownership of 0.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TransThera Sciences (Nanjing) and its competitors. TransThera Sciences (Nanjing)'s current Institutional Ownership is 0.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current Institutional Ownership of 0.09%. The current Institutional Ownership is 0.09%. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current Institutional Ownership is 0.09% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransThera Sciences (Nanjing) Business Description

Other Exchanges 02617:Hong Kong
Address Biotech and Pharmaceutical Valley, 3rd floor, Building 9, Accelerator Phase 2, Jiangbei New Area, Jiangsu Province, Nanjing, CHN, 210032
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score

Get the complete analysis for FRA:J8J

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price